Hepatocellular carcinoma
RecruitingStudy of Fecal Microbiota Transplantation combined with atezolizumab and bevacizumab in patients with unresectable liver cancer who progressed after initial treatment
Study of Fecal Microbiota Transplantation combined with atezolizumab and bevacizumab in patients with unresectable liver cancer who progressed after initial treatment
- Disease:Hepatocellular carcinoma
- Substances:Ascorbic AcidAtezolizumab+11
Italy- Participants:18–64 years · 65+ years
- Substances:Ascorbic Acid









